{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:53:01Z","timestamp":1761864781075,"version":"build-2065373602"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-025-05564-w","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:32:26Z","timestamp":1760455946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pulmonary toxicity induced by carfilzomib: a case report and review of the literature"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-8288","authenticated-orcid":false,"given":"Mateusz","family":"Ziarkiewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Zacny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Basak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laretta","family":"Grabowska-Derlatka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"9","key":"5564_CR1","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","volume":"110","author":"DJ Kuhn","year":"2007","unstructured":"Kuhn DJ, et\u00a0al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin\u2013proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281\u201390.","journal-title":"Blood"},{"issue":"17","key":"5564_CR2","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","volume":"19","author":"TM Herndon","year":"2013","unstructured":"Herndon TM, et\u00a0al. US Food and Drug administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res. 2013;19(17):4559\u201363.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5564_CR3","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, et\u00a0al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327\u201337.","journal-title":"Lancet Oncol"},{"issue":"1","key":"5564_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-018-0583-7","volume":"11","author":"M Dimopoulos","year":"2018","unstructured":"Dimopoulos M, et\u00a0al. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018;11(1):49.","journal-title":"J Hematol Oncol"},{"issue":"10245","key":"5564_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, et\u00a0al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186\u201397.","journal-title":"Lancet"},{"issue":"2","key":"5564_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cas.12335","volume":"105","author":"K Yoshizawa","year":"2014","unstructured":"Yoshizawa K, et\u00a0al. Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization. Cancer Sci. 2014;105(2):195\u2013201.","journal-title":"Cancer Sci"},{"key":"5564_CR7","first-page":"430141","volume":"2012","author":"E Vandeix","year":"2012","unstructured":"Vandeix E, et\u00a0al. Bortezomib-induced bronchiolitis obliterans organizing pneumonia. Case Rep Pulmonol. 2012;2012:430141.","journal-title":"Case Rep Pulmonol"},{"issue":"7","key":"5564_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/jjco\/hys074","volume":"42","author":"T Yamaguchi","year":"2012","unstructured":"Yamaguchi T, Sasaki M, Itoh K. Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma. Jpn J Clin Oncol. 2012;42(7):637\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"5564_CR9","doi-asserted-by":"publisher","first-page":"2913124","DOI":"10.1155\/2018\/2913124","volume":"2018","author":"P Kharel","year":"2018","unstructured":"Kharel P, et\u00a0al. Bortezomib-induced pulmonary toxicity: a case report and review of literature. Case Rep Med. 2018;2018:2913124.","journal-title":"Case Rep Med"},{"issue":"3","key":"5564_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2006-03-011494","volume":"108","author":"JE Boyer","year":"2006","unstructured":"Boyer JE, et\u00a0al. Severe pulmonary complication after bortezomib treatment for multiple myeloma. Blood. 2006;108(3):1113.","journal-title":"Blood"},{"issue":"9","key":"5564_CR11","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1182\/blood-2005-11-4541","volume":"107","author":"S Miyakoshi","year":"2006","unstructured":"Miyakoshi S, et\u00a0al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107(9):3492\u20134.","journal-title":"Blood"},{"issue":"6","key":"5564_CR12","first-page":"407","volume":"10","author":"B Saglam","year":"2020","unstructured":"Saglam B, et\u00a0al. Bortezomib induced pulmonary toxicity: a case report and review of the literature. Am J Blood Res. 2020;10(6):407\u201315.","journal-title":"Am J Blood Res"},{"issue":"6","key":"5564_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/01.mjt.0000245224.20913.0d","volume":"13","author":"A Ohri","year":"2006","unstructured":"Ohri A, Arena FP. Severe pulmonary complications in African-American patient after bortezomib therapy. Am J Ther. 2006;13(6):553\u20135.","journal-title":"Am J Ther"},{"issue":"7","key":"5564_CR14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau P, et\u00a0al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953\u201364.","journal-title":"Lancet Oncol"},{"issue":"21","key":"5564_CR15","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1182\/blood.V124.21.5731.5731","volume":"124","author":"A Dhakal","year":"2014","unstructured":"Dhakal A, Belur AA, Chandra AB. Bortezomib induced pulmonary toxicity. Blood. 2014;124(21):5731\u20135731.","journal-title":"Blood"},{"key":"5564_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-251173","author":"A Sridhar","year":"2022","unstructured":"Sridhar A, et\u00a0al. Severe pulmonary toxicity related to carfilzomib use: a rare but serious side effect. BMJ Case Rep. 2022. https:\/\/doi.org\/10.1136\/bcr-2022-251173.","journal-title":"BMJ Case Rep"},{"issue":"4","key":"5564_CR17","doi-asserted-by":"publisher","first-page":"492A","DOI":"10.1016\/j.chest.2016.08.506","volume":"150","author":"A Bhagavath","year":"2016","unstructured":"Bhagavath A, Geyer A. Carfilzomib pulmonary toxicity. Chest. 2016;150(4):492A.","journal-title":"Chest"},{"key":"5564_CR18","unstructured":"Keer, N., et\u00a0al. Carfilzomib-related severe pneumonitis, in D34. Lung transplant and drug induced lung disease: case reports. p. A6598-A6598."},{"issue":"4","key":"5564_CR19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.52964\/AMJA.0880","volume":"20","author":"A Marschall","year":"2021","unstructured":"Marschall A, Merino JCF, Gravalos TL. Fatal pulmonary toxicity following carfilzomib administration. Acute Med. 2021;20(4):286\u20139.","journal-title":"Acute Med"},{"issue":"5","key":"5564_CR20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1177\/1078155215588630","volume":"22","author":"AR Lataifeh","year":"2016","unstructured":"Lataifeh AR, Nusair A. Fatal pulmonary toxicity due to carfilzomib (Kyprolis). J Oncol Pharm Pract. 2016;22(5):720\u20134.","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"5564_CR21","doi-asserted-by":"publisher","first-page":"204589402110493","DOI":"10.1177\/20458940211049300","volume":"11","author":"JZ Yang","year":"2021","unstructured":"Yang JZ, et\u00a0al. Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma. Pulm Circ. 2021;11(4):20458940211049300.","journal-title":"Pulm Circ"},{"issue":"6","key":"5564_CR22","doi-asserted-by":"publisher","first-page":"NP37","DOI":"10.1177\/0300891621990427","volume":"107","author":"A Rago","year":"2021","unstructured":"Rago A, et al. Pulmonary arterial hypertension in a patient with multiple myeloma during carfilzomib treatment: in search of better management. Tumori. 2021;107(6):NP37-40. https:\/\/doi.org\/10.1177\/0300891621990427.","journal-title":"Tumori."},{"issue":"8","key":"5564_CR23","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1177\/10781552231190039","volume":"29","author":"R Ghasoub","year":"2023","unstructured":"Ghasoub R, et\u00a0al. Carfilzomib-induced life-threatening lung injury in refractory multiple myeloma. J Oncol Pharm Pract. 2023;29(8):2041\u20134.","journal-title":"J Oncol Pharm Pract"},{"key":"5564_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","volume":"60","author":"LD Fricker","year":"2020","unstructured":"Fricker LD. Proteasome inhibitor drugs. Annu Rev Pharmacol Toxicol. 2020;60:457\u201376.","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05564-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05564-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05564-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:32:27Z","timestamp":1760455947000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05564-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5564"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05564-w","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been sent to the Institutional Review Board of the Medical University of Warsaw, Poland; however, the need for acceptance was waived as the study does not include any prospective intervention.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following financial interests\/personal relationships that may be considered as potential competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"510"}}